ReviewFrontiers in immunology2026
Efferocytosis: unifying pathogenic hub in metabolic disorders-mechanistic landscapes, targeted therapies and translational bottlenecks.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic disorders, such as obesity, diabetes mellitus, metabolic dysfunction-associated steatotic liver disease, and atherosclerosis, collectively pose a severe global public health crisis. Systemic chronic low-grade inflammation caused by metabolic stress, namely metaflammation, is universally present in metabolic disorders. This pathological trait drives causal interactions and synergistic deterioration among distinct metabolic disorders, and cannot be efficiently alleviated by conventional clinical anti-inflammatory drugs. Efferocytosis refers to the programmed clearance of apoptotic cells mediated by phagocytes such as macrophages. It is indispensable for maintaining innate immune homeostasis, facilitating the resolution of metaflammation, and balancing metabolic microenvironments. This review comprehensively outlines the core characteristics and molecular mechanisms of efferocytosis, illustrates its regulatory networks in multiple metabolic disorders, concludes current therapeutic strategies targeting efferocytosis for metabolic disorders, and discusses the controversies and translational challenges of relevant interventions. This review systemically elucidates the shared core pathological mechanisms of defective efferocytosis underlying the interactive and progressive progression of multiple metabolic disorders, lays a theoretical foundation for the development of early diagnostic biomarkers and novel immune-targeted intervention strategies for metaflammation, and provides evidence-based rationale for translational research and clinical practice of related metabolic disorders.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.